Curis (CRIS) Competitors $3.75 +0.05 (+1.35%) (As of 10:20 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CRIS vs. XFOR, AGEN, FBIO, SABS, BOLT, MTEM, NTGN, CDTX, AMGN, and VRTXShould you be buying Curis stock or one of its competitors? The main competitors of Curis include X4 Pharmaceuticals (XFOR), Agenus (AGEN), Fortress Biotech (FBIO), SAB Biotherapeutics (SABS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Neon Therapeutics (NTGN), Cidara Therapeutics (CDTX), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector. Curis vs. X4 Pharmaceuticals Agenus Fortress Biotech SAB Biotherapeutics Bolt Biotherapeutics Molecular Templates Neon Therapeutics Cidara Therapeutics Amgen Vertex Pharmaceuticals X4 Pharmaceuticals (NASDAQ:XFOR) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk. Do analysts rate XFOR or CRIS? X4 Pharmaceuticals presently has a consensus price target of $2.88, suggesting a potential upside of 744.59%. Curis has a consensus price target of $23.00, suggesting a potential upside of 521.62%. Given X4 Pharmaceuticals' higher probable upside, equities research analysts plainly believe X4 Pharmaceuticals is more favorable than Curis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Curis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer XFOR or CRIS? In the previous week, X4 Pharmaceuticals had 10 more articles in the media than Curis. MarketBeat recorded 18 mentions for X4 Pharmaceuticals and 8 mentions for Curis. Curis' average media sentiment score of 0.20 beat X4 Pharmaceuticals' score of -0.02 indicating that Curis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment X4 Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Curis 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor XFOR or CRIS? Curis received 617 more outperform votes than X4 Pharmaceuticals when rated by MarketBeat users. Likewise, 67.78% of users gave Curis an outperform vote while only 66.96% of users gave X4 Pharmaceuticals an outperform vote. CompanyUnderperformOutperformX4 PharmaceuticalsOutperform Votes7566.96% Underperform Votes3733.04% CurisOutperform Votes69267.78% Underperform Votes32932.22% Is XFOR or CRIS more profitable? X4 Pharmaceuticals has a net margin of 0.00% compared to Curis' net margin of -443.35%. X4 Pharmaceuticals' return on equity of -236.19% beat Curis' return on equity.Company Net Margins Return on Equity Return on Assets X4 PharmaceuticalsN/A -236.19% -75.14% Curis -443.35%-923.37%-78.35% Which has more risk and volatility, XFOR or CRIS? X4 Pharmaceuticals has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.35, indicating that its stock price is 235% more volatile than the S&P 500. Which has preferable valuation and earnings, XFOR or CRIS? Curis has higher revenue and earnings than X4 Pharmaceuticals. X4 Pharmaceuticals is trading at a lower price-to-earnings ratio than Curis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 PharmaceuticalsN/AN/A-$101.17M-$0.09-3.78Curis$10.26M2.16-$47.41M-$7.81-0.47 Do institutionals and insiders hold more shares of XFOR or CRIS? 72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 30.0% of Curis shares are held by institutional investors. 1.6% of X4 Pharmaceuticals shares are held by company insiders. Comparatively, 5.7% of Curis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryCuris beats X4 Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get Curis News Delivered to You Automatically Sign up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRIS vs. The Competition Export to ExcelMetricCurisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.66M$2.93B$5.01B$8.81BDividend YieldN/A1.89%5.16%4.06%P/E Ratio-0.4745.25134.3717.77Price / Sales2.16360.241,158.6875.18Price / CashN/A160.0933.5332.53Price / Book1.113.734.674.68Net Income-$47.41M-$41.63M$119.07M$226.08M7 Day Performance-7.04%-4.73%-1.83%-1.04%1 Month Performance-30.58%-6.53%-3.62%1.04%1 Year Performance-56.57%25.63%31.63%26.28% Curis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRISCuris2.0186 of 5 stars$3.75+1.4%$23.00+513.3%-56.3%$22.43M$10.02M-0.4849XFORX4 Pharmaceuticals4.0062 of 5 stars$0.34-0.4%$2.88+748.1%-57.4%$57.82MN/A0.0080Analyst RevisionAGENAgenus3.8851 of 5 stars$2.68+0.4%$10.00+273.1%-82.0%$62.87M$156.31M0.00389Analyst RevisionFBIOFortress Biotech3.0653 of 5 stars$1.58+0.6%$13.67+765.0%-43.9%$43.61M$84.51M0.00186Analyst ForecastAnalyst RevisionSABSSAB Biotherapeutics3.5154 of 5 stars$3.11+1.6%$12.40+298.7%+267.0%$28.71M$2.24M0.00140BOLTBolt Biotherapeutics3.3839 of 5 stars$0.56-2.5%$3.50+529.5%-37.7%$21.28M$7.88M0.00100MTEMMolecular Templates2.2363 of 5 stars$0.39-0.3%N/A-92.0%$2.55M$57.31M0.0062Insider TradeNTGNNeon TherapeuticsN/A$3.07flatN/AN/A$88.93MN/A-1.07102CDTXCidara Therapeutics4.1934 of 5 stars$17.79+17.7%$30.50+71.4%+0.9%$125.42M$63.90M-0.7090High Trading VolumeAMGNAmgen4.9132 of 5 stars$286.05-0.6%$333.57+16.6%+8.5%$153.76B$28.19B36.8626,700Ex-DividendShort Interest ↓Positive NewsVRTXVertex Pharmaceuticals4.0527 of 5 stars$446.01-1.2%$499.12+11.9%+26.5%$114.86B$9.87B0.005,400Analyst DowngradeNews CoveragePositive News Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Agenus Competitors Fortress Biotech Competitors SAB Biotherapeutics Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Neon Therapeutics Competitors Cidara Therapeutics Competitors Amgen Competitors Vertex Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRIS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
